Equities Analysts Offer Predictions for STOK Q1 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.53) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.54) EPS.

Several other research firms have also issued reports on STOK. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. Chardan Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Stock Down 6.9 %

NASDAQ STOK opened at $8.26 on Thursday. Stoke Therapeutics has a 52 week low of $5.60 and a 52 week high of $17.58. The company has a 50 day moving average price of $9.50 and a 200 day moving average price of $11.51. The firm has a market cap of $437.51 million, a PE ratio of -3.93 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million.

Institutional Trading of Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new position in shares of Stoke Therapeutics in the fourth quarter valued at approximately $63,000. Teacher Retirement System of Texas acquired a new stake in Stoke Therapeutics in the fourth quarter valued at $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics during the fourth quarter worth $124,000. Tower Research Capital LLC TRC raised its holdings in shares of Stoke Therapeutics by 70.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after acquiring an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in shares of Stoke Therapeutics during the fourth quarter valued at approximately $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.